Posters recently presented by ARI scientists, listed below in reverse chronological order, may be viewed as PDF files.
14th Conference on Retroviruses and Opportunistic Infections
Los Angeles, CA, February 25–28, 2007
Aweeka FT, Tierney C, Stek A, Sun X, Cohn SE, Coombs R, Lizak P, Kmack AM, Klingman K, and Sha BE for the ACTG 5153s team. ACTG A5153s, a substudy for A5150: Pharmacokinetic exposure and virological response in HIV-1–infected pregnant women treated with protease inhibitors.
Beatty G, Chow L, Lipshutz G, Pillai S, Hoh R, Spotts G, Martin J, Deeks SG, Liegler T. HIV-1 from seminal fluid exhibits stable high-levels of drug resistance mutations in patients maintained on incompletely suppressive antiretroviral regimens.
Butler L, Mosam A, Kiepiela P, Rosenthal1 P, Dorsey G, Mbisa G, Whitby D, Brander C, Scadden D, Dollard S, Martin J. Lack of age dependence in KSHV seroprevalence among children in a population-based study in South Africa: Evidence for at least two epidemiologic patterns of KSHV transmission in Africa.
Emu B, Sinclair E, Shacklett B, Ferre A, Hoh R, Hatano H, Martin J, McCune JM, and DeeksS. High levels of gag-specific CD8+ IFNγ+ IL-2+T cell response are correlated with the expression of protective HLA types among HIV-infected virologic controllers.
Hatano H, Morris M, Ferre A, Williamson DW, Hoh R, McCune JM, Martin JN, Shacklett BL, and Deeks SG. Genetic determinants of durable control of HIV replication in the absence of antiretroviral therapy.
Hecht F, Wellman R, Busch M, Little S, Markowitz M, Collier A, Margolick J, Norris P, Routy J-P, Holte S, and the Acute Infection Early Disease Research Program. Use of quantitative results from HIV antibody EIAs to identify persons in early post-seroconversion periods.
Hunt PW, Cao H, Martin JN, Baker C, Jones N, Ssewanyana I, Andia I, Emenyonu N, Bangsberg DR, and Deeks SG. Untreated HIV-infected individuals in Uganda have higher CD8+ T cell activation levels than untreated HIV-infected individuals in North America.
Hunt PW, Huang W, Coakley E, Petropoulos C, Bates M, Hoh R, Deeks SG, and Martin JN. Longitudinal evaluation of viral co-receptor tropism switches among HIV-infected patients with drug-resistant viremia.
Luetkemeyer A, Charlebois ED, Flores LL, Bangsberg DR, Deeks SG, Martin JN, Havlir DV1. Comparison of an interferon gamma release assay to conventional tuberculin skin testing for latent TB diagnosis in HIV-infected individuals.
Martin J, Neilands T, Krone M, Coakley E, Lie Y, Pesano R, Bates M, Weidler J, and Deeks S. Utility of pol replication capacity in predicting immunologic course among HIV-infected patients with drug-resistant viremia.
Petersen ML, Wang Y, van der Laan MJ, Guzman D, Riley E, and Bangsberg DR. Pill box organizers are associated with improved HIV antiretroviral adherence and viral suppression: A marginal structural model analysis.
Ruel TD, Achan J, Gasasira AF, Charlebois ED, Rosenthal PJ, Dorsey G, Kamya MR, Kekitiinwa A, Wong J, Havlir D, and the CHAMP team. Dramatic reductions in HIV RNA among HIV-infected children with acute measles in Uganda.
Sohn AH, Quoc Thinh, Xuan Lien T, Truong Giang L, Huu Khanh T, Wara DW, Cachafeiro A, Rutherford GW. The ultrasensitive p24 antigen assay is comparable to DNA PCR for early infant diagnosis, Ho Chi Minh City, Vietnam.
Srikantiah P, Walusimbi M, Kose Kayanja H, Mayanja-Kizza H, Mugerwa RD, Lin R, Charlebois ED, Boom WH, Whalen CC, Havlir DV. Safety and early virologic response of zidovudine/lamivudine/abacavir for patients co-infected with HIV and tuberculosis (TB) in Uganda.
Srikantiah P, Walusimbi M, Mayanja-Kizza H, Kose Kayanja H, Mugerwa RD, Harvey RA, Charlebois ED, Boom WH, Whalen CC, Havlir DV. Unexpected low-level viremia among HIV-infected Ugandans with untreated active tuberculosis (TB).
Truong H-HM, Fritz K, McFarland W, Hartogensis W, Fiamma A, Coates TJ, and Morin SF. Recent HIV infections detected at a mobile VCT program in Zimbabwe.
Truong H-HM, Kellogg T, Louie B, Klausner J, Dilley J, and McFarland W. Comparison of incidence estimates derived by laboratory incidence assays and repeat testing data at HIV testing sites in San Francisco.
17th International Conference on the Reduction of Drug Related Harm
Vancouver, Canada, April 30–May 4, 2006
National Conference on Methamphetamine, HIV, and Hepatitis
Salt Lake City, UT, August 18–21, 2005
NIDA Annual Mentored K Awardees Meeting
Bethesda, MD, August 2–4, 2005
Colfax G, Coates TJ, Husnik MH, Huang Y, Buchbinder S, Koblin B, Chesney M, Vittinghoff E, and the EXPLORE study team. Longitudinal patterns of methamphetamine, amyl nitrite, and cocaine use among a cohort of men who have sex with men.
HIV Prevention Leadership Summit
San Francisco, CA, July 30–August 3, 2005
Fuqua V, Imbriani J, Macias O, Sebesta D. Locally-developed innovative strategies to increase social capital and to foster community building among Black, Latino, Asian, older, midlife, and queer youth gay men.
3rd IAS Conference on HIV Pathogenesis and Treatment
Rio de Janiero, Brazil, July 24–27, 2005
Chin-Hong PV, Vittinghoff E, Benet D, Buchbinder S, Colfax G, Cranston R, Da Costa M, Darragh T, Judson F, Koblin B, Mayer K, Palefsky J. Human papillomavirus is associated with HIV acquisition: The EXPLORE study.
Snyder-Cappione JE, Divekar AA, Maupin GM, Jin X, Demeter LM, Mosmann TR. HIV-specific cytotoxic cell frequencies measured directly ex vivo by the Lysispot assay can be higher or lower than the frequencies of IFNg-secreting cells: Anti-HIV cytotoxicity is not generally impaired relative to other chronic virus responses.
National Medical Association Scientific Assembly and Annual Conference
New York, NY, July 23–28, 2005
16th Biennial Meeting of the International Society for Sexually Transmitted Diseases Research
Amsterdam, Netherlands, July 10–13, 2005
Kinyari TN, White E, Sharma A, Morris M, Bukusi EA, Meier A, Farquhar C, Ngugi EN, Cohen CR. The relationship between sexual partnership characteristics and condom use among young female sex workers in Nairobi, Kenya.
Nguti R, Mugo N, Kwatampora J, Kimani P, Muthama E, Cohen C. Factors associated with behaviour change and time to infection with Neisseria gonorrhoeae and Chlamydia trachomatis in an observational cohort of sex workers in Nairobi, Kenya.
Van der Straten A, Lee M, Montgomery E, Blanchard K, Ramjee G, De Bruyn G, Padian N. Characteristics of non-disclosers of diaphragm use among Southern African women enrolled in an HIV prevention trial.
7th International Congress on AIDS in Asia and the Pacific
Kobe, Japan, July 1–5, 2005
National HIV Prevention Conference
Atlanta, GA, June 12–15, 2005
XIV International HIV Drug Resistance Workshop
Quebec City, Quebec, June 7–11, 2005
Chin-Hong PV, Deeks SG, Liegler T, Krone MR, Grant RM, Hecht FM, Vittinghoff E, Coates TJ, Martin JN. Methamphetamine use is associated with ongoing high-risk sexual behaviors among HIV-infected individuals with drug-resistant virus.
2nd South African AIDS Conference
Durban, South Africa, June 7–10, 2005
American Psychological Society Meeting
Los Angeles, CA, May 26–29, 2005
American Thoracic Society International Conference
San Diego, CA, May 20–25, 2005
Chi A, Beard CB, Crothers K, Jones J, Groner G, Fox M, Eiser S, Bensley M, Huang L. HIV-associated Pneumocystis pneumonia (PCP) with mixed dihydropteroate synthase (DHPS) genotype infection: Predictors and outcomes.
Huang L, Welsh D, Miller R, Bensley M, Carbonnet D, Fox M, Groner G, Chi A, Eiser S, Beard CB, Jones J. Pneumocystis dihydropteroate synthase (SHPS) gene mutations and mortality of HIV-associated Pneumocystis pneumonia (PCP).
3rd International ISPO (International Society of Perinatal Obstetricians) Conference
Dublin, Ireland, May 19–21, 2005
Ojengbede OA, Miller S, Anderson A, Fabamwo O, Akinol OA, Morhason-Bello IO, Hensleigh P. Novel approach in management of severe obstetric hemorrhage: Nigeria hospital experience with the non-pneumatic anti-shock garment (NASG).
American Society of Clinical Oncology Annual Meeting
Orlando, FL, May 13–17, 2005
Bhatia V, Roldan E, Moore DH, Hanks D, Cheng J, Lane K, Benz C, Knudson M, Luce J. Estrogen receptor positivity improves breast cancer survival for all underserved ethnic groups except African Americans.
San Francisco State University College of Science and Engineering Student Showcase
San Francisco, CA, May 9, 2005
American College of Obstetricians and Gynecologists Annual Clinical Meeting
San Francisco, CA, May 7–11, 2005
ARVO (Association for Research in Vision and Ophthalmology) 2005: Global Networking
Ft. Lauderdale, FL, May 1–5, 2005
Haidt SJ, Gascon R, Zhang R, Stern W, Wieland M, Boldrey E, Palmer J, Borrillo L, McGrath M. Blood monocyte expression levels of HLA-DR and CD16 are markers of disease progression in age-related macular degeneration (ARMD).
22nd International Papillomavirus Conference and Clinical Workshop
Vancouver, BC, April 30–May 6, 2005
Chin-Hong PV, Vittinghoff E, Benet D, Buchbinder S, Colfax G, Cranston R, Da Costa M, Darragh T, Judson F, Koblin B, Mayer K, Palefsky J. Age-related incidence of anal human papillomavirus infection among sexually active men who have sex with men: The EXPLORE study.
Sawaya G, Tuveson J, Rubin M, Da Costa M, Darragh T, Shiboski S, Van der Pol B, Moscicki A, Palefsky J, Fancher H, Smith-McCune K. Does Replens vaginal gel interfere with tests for human papillomavirus and other lower genital tract infections?
12th International Workshop on HIV Dynamics and Evolution
Cleveland, OH, April 23–26, 2005
Association of Nurses in AIDS Care Research Summit
Palm Springs, CA, April 22–24, 2005
Keystone Symposia: HIV Pathogenesis and HIV Vaccines—Current Challenges and Future Prospects
Banff, Alberta, April 9–15, 2005
Schweighardt B, Legrand F, Meiklejohn DA, Erickson A, Spotts G, Emu B, Nixon DF, Hecht FM. The development of immune escape mutations within immunodominant Gag epitopes is associated with increased viral replication during structured treatment interruption.
Snyder-Cappione JE, Divekar AA, Maupin GM, Jin X, Demeter LM, Mosmann TR. The Lysispot assay reveals HIV-specific T cells can lyse targets without secreting IFNg directly ex vivo, and the frequencies of IFNg-secreting to cytotoxic cells vary both amongst HIV-specific and in comparison to CMV, EBV responses within individual patients.
7th Annual International Health Conference
San Francisco, CA, April 2, 2005
Population Association of America Annual Meeting
Philadelphia PA, March 31–April 2, 2005
Pathways to Research: A Day of Discovery
San Francisco, CA, March 2, 2005
12th Conference on Retroviruses and Opportunistic Infections
Boston, MA, February 22–25, 2005
Byakika-Tusiime, J, Oyugi J, Musoke P, Ragland K, Bangsberg DR. Adherence approaches 100% with excellent viral load suppression when all HIV infected household members receive antiretroviral treatment.
Fogler J, Mahoney M, Sterkenburg C, Cohan D, Gooze L, Kindrick A, Balano K, Thelin C, Alexander D, Goldschmidt R. Clinicians’ questions about perinatal HIV transmission and perinatal care: Experience of the national HIV telephone consultation service and perinatal hotline.
Gandhi M, Jayawardene A, Aweeka F, Bacchetti P, Ameli N, Cohen M, Gange S, Anastos K, Young M, Holman S, Greenblatt RM. Determination of antiretroviral exposure using hair: A measure of average exposure highly correlated with virologic outcome.
Grant RM, McConnell JJ, Marcus JL, Kreis C, Spotts G, Liegler T, Brennan R, Hecht FM. Higher frequency of apparent HIV-1 superinfection—sequentially expressed dual infection (SEDI)—in recent infection compared to chronic infection.
Roland M, Stablein D, Carlson L, Frassetto L, Murphy B, Keller M, Olthoff K, Blumberg E, Brayman K, Redfield R, Oldach D, Barin B, Stock P. 1- to 3-year outcomes in HIV-infected liver and kidney transplant recipients.
National Conference on West Nile Virus in the U.S.
San Jose, CA, February 8–9, 2005
Busch MP, Tobler LH, McAuley J, Linnen JM, Shyamala V, Robertson GF, Wright DJ, Kleinman SK, Caglioti S. West Nile virus RNA dynamics and antibody evolution based on follow-up of viremic blood donors.
Busch MP, Wright DJ, Tobler LH, Stramer SL, Custer BS, Kleinman SH, Prince HE, Bianco C, Foster G, Petersen LR, Nemo GJ, Glynn SA. West Nile virus (WNV) infections detected by blood donor nucleic-acid amplification technology (NAT) screening and use of NAT data to project national WNV infections in 2003.
Caglioti S, Robertson GF, McAuley J, Kleinman SH, Tobler LH, Kamel H, Linnen JM, Shyamala V, Tomasulo PA, Busch MP. Screening the blood supply for West Nile virus RNA by nucleic acid amplification testing (NAT).
Tobler LH, Prince H, Valks A, Dille B, Andrews WW, Harrington C, Phelps BH, Munneke B, Morgan L, Ostboe P, Gefter N, Busch MP. Relative performance of four West Nile virus serological assays in thirteen seroconversion panels.